Follow-Up Studies on Epstein &amp;ndash; Barr virus IgA/VCA Antibody-Positive Persons in Zangwu County, China

Zeng, Yi; Zhong, Jing; Li, L.Y.; Wang, P.Z.; Tang, Huifen; Ma, Yanyi; Zhu, Jie; Pan, Weimin; Liu, Y.X.; Wei, Zhao; Chen, J.Y.; YongKun, Mo; Li, E.J.; Tan, Bing

doi:10.1159/000149391

Cited by 93 publications

(55 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overall prediction rate (56/131) achieved by serologic screening conducted at the time of enrollment is similar to that reported by Chien et al (2001), but lower than that achieved by Yi et al (1980) and Zeng et al (1983). The cumulative incidence of the entire study population calculated over 15 years is 21 per 10 5 person-year.…”

Section: Resultssupporting

confidence: 64%

“…It has a strong association with the human herpesvirus, Epstein -Barr virus (EBV) (Raab-Traub, 2002), with general elevation of serum EBV antibody level being an outstanding feature of the tumour (Olds et al, 1966;Henle et al, 1970;Henle and Henle, 1976;Ho et al, 1978a;Zeng et al, 1983;Cheng et al, 2002;Chan et al, 2003;Fachiroh et al, 2004). EBV antibody screening in sera of populations in high incidence areas for NPC can be useful in predicting onset of the cancer (Yi et al, 1980;Zeng et al, 1983;Chien et al, 2001;Ji et al, 2003a, b). This is presumed to reflect rises in antibody levels at an early stage in cancer development (Ho et al, 1978a;Cheng et al, 2002).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Sustained elevation of Epstein–Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma

Ji¹,

Wang²,

Yu³

et al. 2007

Br J Cancer

156

138

View full text Add to dashboard Cite

We have monitored Epstein -Barr virus (EBV) IgA antibody levels of 39 nasopharyngeal carcinoma (NPC) cases for up to 15 years before clinical onset of NPC, and assessed preclinical serologic status of another 68 cases. Our results identify a serologic window preceding diagnosis when antibody levels are raised and sustained. This window can persist for as long as 10 years, with a mean duration estimated to as 37728 months. Ninety-seven of these 107 NPC cases exhibited such a window. Cases that did not may reflect individual antibody response to EBV. Serologic screening at enrollment identified those cases who had already entered the window and became clinically manifested earlier (median ¼ 28 months) than those who entered the window after enrollment (median ¼ 90 months). The former account for 19 of 21 cases diagnosed within 2 years of screening. Nasopharyngeal carcinoma risk levels among seropositive subjects were also highest during this period. Both prediction rates and risk levels declined thereafter; cases detected at later times were composed of increasing proportions of individuals who entered the serological window after screening. Our findings establish EBV antibody as an early marker of NPC and suggest that repeated screening to monitor cases as they enter this window has considerable predictive value, with practical consequences for cancer treatment.

show abstract

Section: Resultssupporting

confidence: 64%

mentioning

confidence: 99%

Sustained elevation of Epstein–Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma

Ji¹,

Wang²,

Yu³

et al. 2007

Br J Cancer

156

138

View full text Add to dashboard Cite

show abstract

“…1 Although several previous studies [2][3][4][5] have reported on the use of EBV serology for screening and early detection of NPC, the role of EBV DNA detection as a screening test for NPC remains to be defined. Circulating cell-free EBV DNA is detectable in the plasma of 96% of NPC patients 6 by quantitative real-time polymerase chain reaction (PCR) and has been shown to be a useful marker in prognostication 7 as well as residual disease detection.…”

Section: Dear Sirmentioning

confidence: 99%

Plasma Epstein‐Barr virus (EBV) DNA: Role as a screening test for nasopharyngeal carcinoma (NPC)?

Wong

Lai

Tsui

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

Dear Sir,We read with interest the recent article in this journal on screening for family members of nasopharyngeal carcinoma (NPC) patients by serologic tests against Epstein-Barr virus (EBV). 1 Although several previous studies [2][3][4][5] have reported on the use of EBV serology for screening and early detection of NPC, the role of EBV DNA detection as a screening test for NPC remains to be defined. Circulating cell-free EBV DNA is detectable in the plasma of 96% of NPC patients 6 by quantitative real-time polymerase chain reaction (PCR) and has been shown to be a useful marker in prognostication 7 as well as residual disease detection. 8 Studies on EBV DNA detection, however, are performed on known NPC patients but not in the general population. We report our preliminary results on plasma EBV DNA detection, in association with EBV serology, as screening tests for NPC in the setting of routine health assessment.In the 6-month period from July to December 2004, a total of 1,475 blood samples were referred from the Health Assessment Centre of our hospital for detection of EBV status as part of body checkup. They comprised 875 male patients and 600 female patients with a median age of 49 years (range 16-92 years). None of them had prior history of EBV-related malignancies. All patients were tested for cell-free plasma EBV DNA level, and when the result was positive, serum samples were retrieved for EBV serologic testing.The RealArt EBV LC PCR Kit (Artus, Hamburg, Germany), working on the LightCycler instrument (Roche Diagnostics, Mannheim, Germany), was employed for plasma EBV DNA detection. The EBV LC PCR Master reagent contained reagents and enzymes for the specific amplification of a 97 bp region of the EBNA1 gene of the EBV genome. Quantification standards were provided with the kit and were included in each run so as to generate the standard curve for EBV load determination. An external quantified EBV viral DNA control (Advanced Biotechnologies, Columbia, MD) was included in each run to check the performance of the assay. Serum EBV VCA IgA and EA IgA antibody levels were determined by indirect immunofluorescence assay on Raji cells and B95-8 cells induced to express EA and VCA, respectively (purchased from the Department of Microbiology, The University of Hong Kong). Antibody titer was defined as the highest dilution that yielded a positive fluorescent signal. Cutoff values for positivity were set at 1:40 for VCA IgA and 1:10 for EA IgA.The presence of EBV DNA was detected in 33 patients (2.24%). Among them, 4 were positive for VCA IgA in which 1 patient was also positive for EA IgA. The clinical records of these patients were reviewed. The only patient with detectable EBV DNA (118 copies/mL) and positive VCA (titer 1:80) as well as EA (titer 1:40) IgA was a 48-year-old man who was referred for otorhinolaryngology (ENT) consultation. Endoscopic examination of the nasopharynx and biopsy showed undifferentiated carcinoma consistent with NPC. Another patient, a 20-year-old man who showed detectable EBV DNA (4...

show abstract

“…Although several prior studies (Zeng et al, 1982;Zeng et al, 1983;Zeng et al, 1985;Tsang et al, 2004) have demonstrated on the use of EBV serology for screening and early detection of NPC, the role of EBV DNA detection as a screening test for NPC remains inconclusive. Previous research has reported that cell-free EBV DNA can be quantitatively measured in the blood of NPC patients using polymerase chain reaction (PCR) technique Shotelersuk et al, 2000;Lin et al, 2001;Chan et al, 2003;Fan et al, 2004).…”

Section: Introductionmentioning

confidence: 99%

Systematic Review on Epstein-Barr Virus (EBV) DNA in Diagnosis of Nasopharyngeal Carcinoma in Asian Populations

Han¹,

Xu²,

Zhang³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Follow-Up Studies on Epstein – Barr virus IgA/VCA Antibody-Positive Persons in Zangwu County, China

Cited by 93 publications

References 3 publications

Sustained elevation of Epstein–Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma

Sustained elevation of Epstein–Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma

Plasma Epstein‐Barr virus (EBV) DNA: Role as a screening test for nasopharyngeal carcinoma (NPC)?

Systematic Review on Epstein-Barr Virus (EBV) DNA in Diagnosis of Nasopharyngeal Carcinoma in Asian Populations

Contact Info

Product

Resources

About